Takeo Kosaka

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 63

Top Topics

Tyrosine Kinase

Radical Prostatectomy

Renal Cell Carcinoma

Top Venues

IJU case reports

Annals of surgical oncology

International journal of clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Naoki Haratake, Ayako Nakashoji, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Takeo Kosaka, Mototsugu Oya, Donald W Kufe
MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells. Cell death discovery 10 (1) (2024)
Minami Omura, Takeo Kosaka, Hiroaki Kobayashi, Keisuke Shigeta, Kazuhiro Matsumoto, Satoshi Hara, Eiji Kikuchi, Shuji Mikami, Hideyuki Saya, Yasufumi Sato, Mototsugu Oya
ASO Author Reflections: Vasohibin-1 as a Biomarker for Chemotherapeutic Response in Patients with Advanced Bladder Cancer. Annals of surgical oncology 31 (6) (2024)
Kohei Hashimoto, Takeo Kosaka, Naoki Terada, Takahiro Kimura, Norio Nonomura, Hiroyoshi Suzuki, Hiroji Uemura
Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2023. International journal of urology : official journal of the Japanese Urological Association (2024)
Hiroshi Hongo, Takeo Kosaka, Ken-Ichi Takayama, Yuto Baba, Yota Yasumizu, Koji Ueda, Yutaka Suzuki, Satoshi Inoue, Himisha Beltran, Mototsugu Oya
G-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer. PNAS nexus 3 (1) (2024)
Minami Omura, Takeo Kosaka, Hiroaki Kobayashi, Keisuke Shigeta, Kazuhiro Matsumoto, Satoshi Hara, Eiji Kikuchi, Shuji Mikami, Hideyuki Saya, Yasufumi Sato, Mototsugu Oya
Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy. Annals of surgical oncology (2024)
Minami Omura, Takeo Kosaka, Hiroaki Kobayashi, Keisuke Shigeta, Kazuhiro Matsumoto, Satoshi Hara, Eiji Kikuchi, Shuji Mikami, Hideyuki Saya, Yasufumi Sato, Mototsugu Oya
Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy. Annals of surgical oncology 31 (5) (2024)
Kazuhiro Matsumoto, Takeo Kosaka, Toshikazu Takeda, Keishiro Fukumoto, Yota Yasumizu, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Hiroshi Asanuma, Mototsugu Oya
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI). International journal of clinical oncology (2024)
Kazuhiro Matsumoto, Takeo Kosaka, Toshikazu Takeda, Keishiro Fukumoto, Yota Yasumizu, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Hiroshi Asanuma, Mototsugu Oya
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI). International journal of clinical oncology 29 (8) (2024)
Minami Omura, Takeo Kosaka, Hiroaki Kobayashi, Keisuke Shigeta, Kazuhiro Matsumoto, Satoshi Hara, Eiji Kikuchi, Shuji Mikami, Hideyuki Saya, Yasufumi Sato, Mototsugu Oya
ASO Author Reflections: Vasohibin-1 as a Biomarker for Chemotherapeutic Response in Patients with Advanced Bladder Cancer. Annals of surgical oncology 31 (6) (2024)
Kazuhiro Matsumoto, Takeo Kosaka, Toshikazu Takeda, Keishiro Fukumoto, Yota Yasumizu, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Hiroshi Asanuma, Mototsugu Oya
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI). International journal of clinical oncology 29 (8) (2024)
Kazuhiro Matsumoto, Takeo Kosaka, Toshikazu Takeda, Keishiro Fukumoto, Yota Yasumizu, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Hiroshi Asanuma, Mototsugu Oya
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI). International journal of clinical oncology 29 (8) (2024)
Kazuhiro Matsumoto, Takeo Kosaka, Toshikazu Takeda, Keishiro Fukumoto, Yota Yasumizu, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Hiroshi Asanuma, Mototsugu Oya
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI). International journal of clinical oncology 29 (8) (2024)
Kohei Hashimoto, Takeo Kosaka, Naoki Terada, Takahiro Kimura, Norio Nonomura, Hiroyoshi Suzuki, Hiroji Uemura
Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2023. International journal of urology : official journal of the Japanese Urological Association 31 (9) (2024)
Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Naoki Haratake, Ayako Nakashoji, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Takeo Kosaka, Mototsugu Oya, Donald W Kufe
MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells. Cell death discovery 10 (1) (2024)
Minami Omura, Takeo Kosaka, Hiroaki Kobayashi, Keisuke Shigeta, Kazuhiro Matsumoto, Satoshi Hara, Eiji Kikuchi, Shuji Mikami, Hideyuki Saya, Yasufumi Sato, Mototsugu Oya
Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy. Annals of surgical oncology 31 (5) (2024)
Hiroshi Hongo, Takeo Kosaka, Ken-Ichi Takayama, Yuto Baba, Yota Yasumizu, Koji Ueda, Yutaka Suzuki, Satoshi Inoue, Himisha Beltran, Mototsugu Oya
G-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer. PNAS nexus 3 (1) (2024)
Minami Omura, Takeo Kosaka, Hiroaki Kobayashi, Keisuke Shigeta, Kazuhiro Matsumoto, Satoshi Hara, Eiji Kikuchi, Shuji Mikami, Hideyuki Saya, Yasufumi Sato, Mototsugu Oya
ASO Author Reflections: Vasohibin-1 as a Biomarker for Chemotherapeutic Response in Patients with Advanced Bladder Cancer. Annals of surgical oncology (2024)
Minami Omura, Takeo Kosaka, Hiroaki Kobayashi, Keisuke Shigeta, Kazuhiro Matsumoto, Satoshi Hara, Eiji Kikuchi, Shuji Mikami, Hideyuki Saya, Yasufumi Sato, Mototsugu Oya
Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy. Annals of surgical oncology (2024)
Minami Omura, Takeo Kosaka, Hiroaki Kobayashi, Keisuke Shigeta, Kazuhiro Matsumoto, Satoshi Hara, Eiji Kikuchi, Shuji Mikami, Hideyuki Saya, Yasufumi Sato, Mototsugu Oya
Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy. Annals of surgical oncology (2024)
Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Naoki Haratake, Ayako Nakashoji, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Takeo Kosaka, Mototsugu Oya, Donald W Kufe
MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells. Cell death discovery 10 (1) (2024)
Shinnosuke Fujiwara, Takeo Kosaka, Yoshinori Nishimoto, Ken Kamisawa, Keitaro Watanabe, Yuto Baba, Toshikazu Takeda, Kazuhiro Matsumoto, Mototsugu Oya
Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel. The Prostate (2023)
Ryohei Kufukihara, Toshikazu Takeda, Kyohei Hakozaki, Yota Yasumizu, Nobuyuki Tanaka, Kazuhiro Matsumoto, Shinya Morita, Takeo Kosaka, Ryuichi Mizuno, Hiroshi Asanuma, Kazutoshi Miyashita, Isao Kurihara, Mototsugu Oya
Predictors of renal function after adrenalectomy in patients with Cushing or subclinical Cushing syndrome. International journal of urology : official journal of the Japanese Urological Association (2022)
Hiroaki Kobayashi, Takeo Kosaka, Kohei Nakamura, Tokuhiro Kimura, Hiroshi Nishihara, Mototsugu Oya
Genomic analysis of aggressive ductal adenocarcinoma of the prostate. Cancer medicine (2022)
Ken Kamisawa, Takeo Kosaka, Kohei Nakamura, Yota Yasumizu, Hiroshi Hongo, Toshikazu Takeda, Kazuhiro Matsumoto, Hiroshi Nishihara, Mototsugu Oya
Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations. Cancer science 113 (9) (2022)
Tsukasa Masuda, Takeo Kosaka, Kohei Nakamura, Hiroshi Hongo, Kazuyuki Yuge, Hiroshi Nishihara, Mototsugu Oya
Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review. BMC medical genomics 15 (1) (2022)
Masashi Arai, Takeo Kosaka, Yota Yasumizu, Toshikazu Takeda, Kazuhiro Matsumoto, Mototsugu Oya
Androgen deprivation therapy duration is significantly associated with Testosterone recovery in Japanese patients with prostate cancer. International journal of urology : official journal of the Japanese Urological Association (2022)
Tomohiro Iwasawa, Takeo Kosaka, Shinya Morita, Shuji Mikami, Kohei Nakamura, Hiroshi Hongo, Hiroshi Nishihara, Mototsugu Oya
A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report. BMC medical genomics 15 (1) (2022)
Tomohiro Iwasawa, Takeo Kosaka, Yota Yasumizu, Hiroshi Hongo, Yoshinori Yanai, Yuto Baba, Kazuhiro Matsumoto, Kohei Nakamura, Hiroshi Nishihara, Mototsugu Oya
Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series. International journal of clinical oncology 27 (12) (2022)
Takahiro Komori, Takeo Kosaka, Keitaro Watanabe, Tomoki Tanaka, Yota Yasumizu, Hiroshi Hongo, Shuji Mikami, Toshio Ohashi, Mototsugu Oya
Salvage focal brachytherapy in castration-resistant prostate cancer with neuroendocrine differentiation after radiation therapy. IJU case reports 5 (4) (2022)
Yuto Baba, Takeo Kosaka, Hiroaki Kobayashi, Kohei Nakamura, Shuji Mikami, Hiroshi Nishihara, Makoto Nakanishi, Mototsugu Oya
Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation. BMC medical genomics 15 (1) (2022)
Minami Omura, Takeo Kosaka, Eriko Aimono, Kohei Nakamura, Hiroshi Hongo, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya
First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations. IJU case reports 5 (1) (2021)
Hiroshi Hongo, Takeo Kosaka, Yoko Suzuki, Shuji Mikami, Junichi Fukada, Mototsugu Oya
Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways. Scientific reports 11 (1) (2021)
Kazuhiro Matsumoto, Kazuhiro Matsumoto, Koichiro Ogihara, Tetsushi Murakami, Tadatsugu Anno, Kota Umeda, Mizuki Izawa, Yuto Baba, Tansei Sanjo, Kazunori Shojo, Nobuyuki Tanaka, Toshikazu Takeda, Takeo Kosaka, Ryuichi Mizuno, Shuji Mikami, Takeo Kosaka, Mototsugu Oya
The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma. Cancer science 112 (3) (2021)
Tatsuaki Daimon, Takeo Kosaka, Hiroshi Hongo, Eriko Aimono, Kohei Nakamura, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya
Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification. IJU case reports 4 (4) (2021)
Yota Yasumizu, Takeo Kosaka, Hiroshi Hongo, Ryuichi Mizuno, Mototsugu Oya
Cranial nerve palsy caused by metastasis to the skull base in patients with castration-resistant prostate cancer: Three case reports. IJU case reports 4 (2) (2021)
Hiroaki Kobayashi, Takeo Kosaka, Shuji Mikami, Tokuhiro Kimura, Hiroshi Hongo, Michio Kosugi, Yasufumi Sato, Mototsugu Oya
Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in Japan. BMJ open 11 (11) (2021)
Hiroshi Hongo, Takeo Kosaka, Seishi Nakatsuka, Mototsugu Oya
A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing. International cancer conference journal 10 (3) (2021)
Ken-Ichi Takayama, Takeo Kosaka, Takashi Suzuki, Hiroshi Hongo, Mototsugu Oya, Tetsuya Fujimura, Yutaka Suzuki, Satoshi Inouei
Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer. Nature communications 12 (1) (2021)
Kazunori Shojo, Takeo Kosaka, Kohei Nakamura, Hiroshi Hongo, Hiroaki Kobayashi, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya
First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion. IJU case reports 4 (3) (2021)
Hiroshi Hongo, Takeo Kosaka, Yoko Suzuki, Mototsugu Oya
Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening. Prostate cancer and prostatic diseases (2021)
Hiroaki Kobayashi, Takeo Kosaka, Kohei Nakamura, Kazunori Shojo, Hiroshi Hongo, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya
A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations. BMC medical genomics 14 (1) (2021)
Keitaro Watanabe, Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya
Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer. Scientific reports 11 (1) (2021)
Hiroshi Hongo, Takeo Kosaka, Eriko Aimono, Hiroshi Nishihara, Mototsugu Oya
Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report. Diagnostic pathology 15 (1) (2020)
Kazuhiro Matsumoto, Masanori Hasegawa, Takeo Kosaka, Yota Yasumizu, Takeo Kosaka, Ryuichi Mizuno, Shuji Mikami, Akira Miyajima, Donald Kufe, Mototsugu Oya
Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma. Cancer science 111 (10) (2020)
Yota Yasumizu, Hasan Rajabi, Caining Jin, Tsuyoshi Hata, Sean Pitroda, Mark D Long, Masayuki Hagiwara, Wei Li, Qiang Hu, Song Liu, Nami Yamashita, Atsushi Fushimi, Ling Kui, Mehmet Samur, Masaaki Yamamoto, Yan Zhang, Ning Zhang, Deli Hong, Takahiro Maeda, Takeo Kosaka, Kwok-Kin Wong, Mototsugu Oya, Donald W Kufe
Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nature communications 11 (1) (2020)
Yota Yasumizu, Hasan Rajabi, Caining Jin, Tsuyoshi Hata, Sean Pitroda, Mark D Long, Masayuki Hagiwara, Wei Li, Qiang Hu, Song Liu, Nami Yamashita, Atsushi Fushimi, Ling Kui, Mehmet Samur, Masaaki Yamamoto, Yan Zhang, Ning Zhang, Deli Hong, Takahiro Maeda, Takeo Kosaka, Kwok-Kin Wong, Mototsugu Oya, Donald W Kufe
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nature communications 11 (1) (2020)
Yoshinori Yanai, Takeo Kosaka, Kohei Nakamura, Eriko Aimono, Kazuhiro Matsumoto, Shinya Morita, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya
CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression. Cancer science 111 (12) (2020)
Shuji Mikami, Ryuichi Mizuno, Takeo Kosaka, Nobuyuki Tanaka, Naoto Kuroda, Yoji Nagashima, Yasunori Okada, Mototsugu Oya
Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma. Pathology international 70 (10) (2020)
Kota Umeda, Takeo Kosaka, Kohei Nakamura, Toshikazu Takeda, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya
A Japanese patient with ductal carcinoma of the prostate carrying an adenomatosis polyposis coli gene mutation: a case report. Diagnostic pathology 15 (1) (2020)
Mizuki Izawa, Takeo Kosaka, Kohei Nakamura, Junna Oba, Tomoyuki Hishida, Hiroshi Hongo, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya
Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case. IJU case reports 4 (1) (2020)
Koichiro Ogihara, Takeo Kosaka, Shogo Okazaki, Masayuki Hagiwara, Toshikazu Takeda, Kazuhiro Matsumoto, Takeo Kosaka, Shuji Mikami, Hideyuki Saya, Mototsugu Oya
Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer. Cancer science 110 (4) (2019)
Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya
Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report. BMC cancer 19 (1) (2019)
Yoshinori Yanai, Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya
Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report. BMC cancer 19 (1) (2019)
Takeo Kosaka, Hiroshi Hongo, Eriko Aimono, Kazuhiro Matsumoto, Tetsu Hayashida, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya
A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation. Pathology international 69 (12) (2019)
Ken Kamisawa, Takeo Kosaka, Hiroshi Hongo, Ryuichi Mizuno, Mototsugu Oya
Brachytherapy seeds as a nidus for urethral stone formation: A case report. IJU case reports 2 (4) (2019)
Naoya Niwa, Nobuyuki Tanaka, Hiroshi Hongo, Yasumasa Miyazaki, Kimiharu Takamatsu, Ryuichi Mizuno, Eiji Kikuchi, Shuji Mikami, Takeo Kosaka, Mototsugu Oya
TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells. Laboratory investigation; a journal of technical methods and pathology 99 (11) (2019)
Tatsuaki Daimon, Takeo Kosaka, Minoru Horinaga, Junichi Saito, Yoshito Ueyama, Shoji Matsuzaki, Mototsugu Oya
Splenic cord capillary hemangioma with non-islet cell tumor hypoglycemia: a case report. Diagnostic pathology 14 (1) (2019)
Kazuhiro Matsumoto, Hirotaka Akita, Keiichi Narita, Akinori Hashiguchi, Kimiharu Takamatsu, Toshikazu Takeda, Takeo Kosaka, Ryuichi Mizuno, Eiji Kikuchi, Mototsugu Oya, Masahiro Jinzaki
Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer. Prostate cancer and prostatic diseases 22 (4) (2019)
Keisuke Shigeta, Takeo Kosaka, Hiroshi Hongo, Yoshinori Yanai, Kazuhiro Matsumoto, Shinya Morita, Ryuichi Mizuno, Toshiaki Shinojima, Eiji Kikuchi, Mototsugu Oya
Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration. International journal of clinical oncology 24 (5) (2019)
Yoshinori Yanai, Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya
Clinically complete response to abiraterone acetate in a patient with metastatic castration-resistant prostate cancer. IJU case reports 2 (4) (2019)
Takeo Kosaka, Toshiaki Shinojima, Shinya Morita, Mototsugu Oya
Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel. Cancer science 109 (5) (2018)
Takeo Kosaka, Hiroshi Hongo, Keitaro Watanabe, Ryuichi Mizuno, Eiji Kikuchi, Mototsugu Oya
No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer. Cancer chemotherapy and pharmacology 82 (6) (2018)
Hiroshi Hongo, Takeo Kosaka, Mototsugu Oya
Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer. Cancer science 109 (9) (2018)